For: | Lu S, Bennett RG, Kharbanda KK, Harrison-Findik DD. Lack of hepcidin expression attenuates steatosis and causes fibrosis in the liver. World J Hepatol 2016; 8(4): 211-225 [PMID: 26855692 DOI: 10.4254/wjh.v8.i4.211] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v8/i4/211.htm |
Number | Citing Articles |
1 |
Yufang Ding, Karin Yanagi, Fang Yang, Evelyn Callaway, Clint Cheng, Martha E Hensel, Rani Menon, Robert C Alaniz, Kyongbum Lee, Arul Jayaraman. Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice. eLife 2024; 12 doi: 10.7554/eLife.87458
|
2 |
Sara Ahmadi Badi, Ahmad Bereimipour, Pejman Rohani, Shohreh Khatami, Seyed Davar Siadat. Interplay between gut microbiota and the master iron regulator, hepcidin, in the pathogenesis of liver fibrosis. Pathogens and Disease 2024; 82 doi: 10.1093/femspd/ftae005
|
3 |
Sathish Kumar Natarajan, Bailey A. Stringham, Ashley M. Mohr, Cody J. Wehrkamp, Sizhao Lu, Mary Anne Phillippi, Dee Harrison-Findik, Justin L. Mott. FoxO3 increases miR-34a to cause palmitate-induced cholangiocyte lipoapoptosis. Journal of Lipid Research 2017; 58(5): 866 doi: 10.1194/jlr.M071357
|
4 |
Yufang Ding, Karin Yanagi, Fang Yang, Evelyn Callaway, Clint Cheng, Martha E Hensel, Rani Menon, Robert C Alaniz, Kyongbum Lee, Arul Jayaraman. Oral supplementation of gut microbial metabolite indole-3-acetate alleviates diet-induced steatosis and inflammation in mice. eLife 2024; 12 doi: 10.7554/eLife.87458.3
|
5 |
Shanmugam Murugaiha Jeyakumar, Ayyalasomayajula Vajreswari. Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence. World Journal of Hepatology 2022; 14(1): 168-179 doi: 10.4254/wjh.v14.i1.168
|
6 |
Driton Vela. Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker. Molecular Medicine 2018; 24(1) doi: 10.1186/s10020-018-0008-7
|
7 |
Aleksandra A Kolodziejczyk, Danping Zheng, Oren Shibolet, Eran Elinav.
The role of the microbiome in
NAFLD
and
NASH
. EMBO Molecular Medicine 2019; 11(2) doi: 10.15252/emmm.201809302
|
8 |
Meilin Zhu, Hanqing Chen, Shuang Zhou, Lingna Zheng, Xue Li, Runxuan Chu, Wei Chen, Bing Wang, Meng Wang, Zhifang Chai, Weiyue Feng. Iron oxide nanoparticles aggravate hepatic steatosis and liver injury in nonalcoholic fatty liver disease through BMP-SMAD-mediated hepatic iron overload. Nanotoxicology 2021; 15(6): 761 doi: 10.1080/17435390.2021.1919329
|
9 |
Mete Ucdal, Ayse Burus, Basak Celtikci, Hatice Yasemin Balaban. A novel brick on the wall of non-alcoholic fatty liver disease (NAFLD): Nuclear receptor coactivator 4 (NCOA4). Medical Hypotheses 2023; 181: 111203 doi: 10.1016/j.mehy.2023.111203
|
10 |
Han Chen, Ying-Yi Li, Kouki Nio, Hong Tang. Unveiling the Impact of BMP9 in Liver Diseases: Insights into Pathogenesis and Therapeutic Potential. Biomolecules 2024; 14(8): 1013 doi: 10.3390/biom14081013
|
11 |
Hui Chen, Wenshan Zhao, Xuzhen Yan, Tao Huang, Aiting Yang. Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis. Journal of Clinical and Translational Hepatology 2022; 10(4): 577 doi: 10.14218/JCTH.2021.00289
|
12 |
Jing Liu, Bingbing Sun, Huijun Yin, Sijin Liu. Hepcidin. Medicine 2016; 95(14): e3150 doi: 10.1097/MD.0000000000003150
|
13 |
Philipp Bernhardt, Wolfgang Kratzer, Julian Schmidberger, Tilmann Graeter, Beate Gruener. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis. BMC Research Notes 2018; 11(1) doi: 10.1186/s13104-018-3212-1
|
14 |
Marie-Luise Bouvier, Karin Fehsel, Andrea Schmitt, Eva Meisenzahl-Lechner, Wolfgang Gaebel, Martina von Wilmsdorff. Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome. BMC Pharmacology and Toxicology 2022; 23(1) doi: 10.1186/s40360-021-00544-4
|
15 |
Alicia R. Folgueras, Sandra Freitas-Rodríguez, Andrew J. Ramsay, Cecilia Garabaya, Francisco Rodríguez, Gloria Velasco, Carlos López-Otín. Matriptase-2 deficiency protects from obesity by modulating iron homeostasis. Nature Communications 2018; 9(1) doi: 10.1038/s41467-018-03853-1
|
16 |
I. Yu. Torshin, O. A. Gromova, T. E. Bogacheva. Systematic analysis of the relationship between non-alcoholic fatty liver disease and tissue iron overload: promising areas for the use of polypeptide therapy. Experimental and Clinical Gastroenterology 2024; (10): 139 doi: 10.31146/1682-8658-ecg-218-10-139-152
|